CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

Publication Date

2020

Presented At:

2020 Society for Neuro-Oncology’s Virtual Annual Scientific Meeting and Education Day

Content Type

Presentation

Publisher's Site:

View at Publisher Website

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS